Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

Chidamide-based epigenetic therapy for relapsed/refractory Acute Myeloid Leukemia

View Full Paper
Ask AI
Bookmark
Share

Authors

QLQing LiYWYu Wu

Discussion

Loading...

Member takes

Overview

Phase II study demonstrates 53.8% complete remission in R/R AML with chidamide, highlighting venetoclax's efficacy.

Key Points

  • This research aims to evaluate the efficacy and safety of chidamide-based regimens for relapsed/refractory Acute Myeloid Leukemia (AML).
  • Multicenter, prospective phase II study
  • Combination regimens of chidamide with hypomethylating agents, daunorubicin, and cytarabine
  • Comparison with historical control group of patients treated with DA regimen
  • Complete remission rate of 53.8% among 13 treated patients
  • CR rate of 37.5% for chidamide with chemotherapy
  • CR rate of 80% for chidamide with venetoclax

Cite This Study

Li et al. (2025) studied this question.

synapsesocial.com/papers/69362f364fa91c937236d318https://doi.org/10.1182/blood-2025-6982
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Chidamide combined with decitabine, venetoclax, and low-dose cytarabine for relapsed/refractory acute myeloid leukemia: a single-center case series2026
  2. 2Phase 1 study of chidamide in combination with venetoclax, azacitidine, aclarubicin, cytarabine and G-CSF for refractory/relapsed acute myeloid leukemia: clinical safety, efficacy, and correlative analysis2025 · 2 citations
  3. 3MRD-driven HDACi-based therapy post-transplant: a real-world study in high-risk acute myeloid leukemia2026
  4. 4Chidamide induces cell cycle arrest via NR4A3/P21 axis upregulation to suppress relapsed and refractory acute myeloid leukemia2024 · 1 citations
  5. 5Efficacy and safety of azacitidine, venetoclax combined with gha priming regimen in the treatment of adult refractory and relapsed acute myeloid leukemia: A prospective single-arm multicenter study2025